{
    "id": 8828,
    "fullName": "ARID1A loss",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "ARID1A loss indicates loss of the ARID1A gene, mRNA, and protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 8289,
        "geneSymbol": "ARID1A",
        "terms": [
            "ARID1A",
            "B120",
            "BAF250",
            "BAF250a",
            "BM029",
            "C1orf4",
            "CSS2",
            "ELD",
            "hELD",
            "hOSA1",
            "MRD14",
            "OSA1",
            "P270",
            "SMARCF1"
        ]
    },
    "variant": "loss",
    "createDate": "07/07/2015",
    "updateDate": "09/19/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 15420,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ARID1A-deficient colon cancer xenograft models demonstrated an increased response to treatment with an anti-PD-L1 antibody compared to controls (PMID: 29736026).",
            "molecularProfile": {
                "id": 8724,
                "profileName": "ARID1A loss"
            },
            "therapy": {
                "id": 5248,
                "therapyName": "unspecified PD-L1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11347,
                    "pubMedId": 29736026,
                    "title": "ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29736026"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9300,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ERBB2 (HER2) positive breast cancer cells with ARID1A loss demonstrated resistance to AZD8055 in culture (PMID: 27172896).",
            "molecularProfile": {
                "id": 8724,
                "profileName": "ARID1A loss"
            },
            "therapy": {
                "id": 1519,
                "therapyName": "AZD8055",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7065,
                    "pubMedId": 27172896,
                    "title": "Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27172896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9301,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast cancer cells with loss of ARID1A demonstrated restored sensitivity to AZD8055 when additionally treated with MK2206 in culture (PMID: 27172896).",
            "molecularProfile": {
                "id": 8724,
                "profileName": "ARID1A loss"
            },
            "therapy": {
                "id": 4966,
                "therapyName": "AZD8055 + MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7065,
                    "pubMedId": 27172896,
                    "title": "Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27172896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15422,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knockout of ARID1A in ovarian clear cell carcinoma cell lines resulted in increased sensitivity to growth inhibition by JQ1 compared to cells with wild-type ARID1A in culture (PMID: 29760405).",
            "molecularProfile": {
                "id": 8724,
                "profileName": "ARID1A loss"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 50934,
                "name": "ovarian clear cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13211,
                    "pubMedId": 29760405,
                    "title": "ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29760405"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9298,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ERBB2 (HER2) positive breast cancer cells with ARID1A loss demonstrated resistance to Herceptin (trastuzumab) in culture (PMID: 27172896).",
            "molecularProfile": {
                "id": 8724,
                "profileName": "ARID1A loss"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7065,
                    "pubMedId": 27172896,
                    "title": "Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27172896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13910,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an ARID1A-deficient orthotopic ovarian cancer mouse model treated with a PD-L1 antibody demonstrated improved survival and greater decreased tumor volume compared to those treated with control (PMID: 29736026).",
            "molecularProfile": {
                "id": 8724,
                "profileName": "ARID1A loss"
            },
            "therapy": {
                "id": 5248,
                "therapyName": "unspecified PD-L1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11347,
                    "pubMedId": 29736026,
                    "title": "ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29736026"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9302,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a breast cancer cell line with ARID1A loss and harboring ERBB2 (HER2) amplification demonstrated restored sensitivity to Herceptin (trastuzumab) when additionally treated with MK2206 in culture (PMID: 27172896).",
            "molecularProfile": {
                "id": 26813,
                "profileName": "ARID1A loss ERBB2 amp"
            },
            "therapy": {
                "id": 1494,
                "therapyName": "MK2206 + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7065,
                    "pubMedId": 27172896,
                    "title": "Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27172896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 8724,
            "profileName": "ARID1A loss",
            "profileTreatmentApproaches": [
                {
                    "id": 19426,
                    "name": "EZH2 inhibitor",
                    "profileName": "ARID1A loss"
                }
            ]
        },
        {
            "id": 26813,
            "profileName": "ARID1A loss ERBB2 amp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}